Abstract
Purpose: :
To report seven cases of bevacizumab-related uveitis.
Methods: :
Retrospective consecutive case series.
Results: :
Seven eyes of six patients (6 female, 0 male) from a total of 978 injections given in a 3.5 month period developed non-infectious uveitis [incidence = 7/978]. The mean age of patients was 74.6 years (range, 26 to 92). All patients noted symptoms within 1 day of injection. Common signs and symptoms for the seven eyes included corneal edema (5/7), anterior chamber cell (7/7), vitreous cell (6/7), conjunctival injection (7/7), and ocular pain (7/7). No patient presented with a hypopyon. One patient who had undergone bilateral bevacizumab injections required sub-Tenon's triamcinolone acetate in one eye for treatment of persistent uveitis. One patient underwent a diagnostic vitreous aspiration and intravitreal antibiotic injection with negative culture. Five cases resolved with topical prednisolone acetate alone. All cases returned to within one line of baseline visual acuity. All seven eyes had been previously injected with bevacizumab, with a mean number of prior injections of 6.1 (range, 3-12.)
Conclusions: :
We describe in this case series seven cases of bevacizumab-related anterior uveitis noted at our center over a 3.5 month period. Rapid onset of symptoms, lack of hypopyon, and improvement with time and topical steroid treatment are helpful clinical features which may be helpful in distinguishing non-infectious uveitis from infectious endophthalmitis.
Keywords: inflammation • drug toxicity/drug effects • vascular endothelial growth factor